TITLE

QBI Receives Milestone Payment From Mitsubishi-Tokyo

PUB. DATE
February 2000
SOURCE
Worldwide Biotech;Feb2000, Vol. 12 Issue 2, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the milestone payment received by Quark Biotech Inc. from Mitsubishi-Tokyo Pharmaceuticals Inc. under an existing collaborative research and license agreement.
ACCESSION #
2766898

 

Related Articles

  • Quark Biotech receives more cash from Japan.  // Crain's Cleveland Business;9/17/2001, Vol. 22 Issue 38, p29 

    Reports the equity investment of Mitsubishi-Tokyo Pharmaceuticals on Quark Biotech Inc. in Cleveland, Ohio.

  • Quark Biotech earns patent.  // Crain's Cleveland Business;8/5/2002, Vol. 23 Issue 31, p12 

    Reports the patent given to Quark Biotech Inc. for developing a method to identify genes encoding secreted and membranal proteins in Cleveland, Ohio.

  • Biotech firm may build close to Clinic. Thompson, Chris // Crain's Cleveland Business;01/01/2001, Vol. 22 Issue 1, p3 

    Reports on the possibility that biotechnology firm Quark Biotech Inc. will construct a building near the Cleveland Clinic's campus in Cleveland, Ohio. Finalization of plans to transfer to Cleveland; Reasons of Quark for choosing a location near Cleveland Clinic's campus; Plans of Cleveland...

  • Giveaways can't assure our tech future. Thompson, Chris // Crain's Cleveland Business;9/29/2003, Vol. 24 Issue 39, p10 

    Government shouldn't give money to private business. That is the most important lesson of many that should be learned by the announcement that Quark Biotech Inc. is leaving Cleveland for California. Back in 2001, Quark moved to Cleveland from Chicago to follow a researcher, Andrei Gudkov, who...

  • Ecraprost: AS 013, Circulaseâ„¢. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 1, p31 

    Ecraprost [AS 013, Circulaseâ„¢] is a prodrug of prostaglandin E[sub 1] within lipid microspheres that is being developed in Japan by Mitsubishi Pharma Corporation and Asahi Glass. It was originally in development with Welfide Corporation. On 1 October 2001, Welfide Corporation (formerly...

  • Quark Signs Research Pact With Shionogi.  // Worldwide Biotech;Mar2000, Vol. 12 Issue 3, p1 

    Reports on the research and license agreement signed by Quark Biotech Inc. and Shionogi & Co. to discover and analyze genes associated with osteoarthritis.

  • Pfizer licenses gene for possible AMD therapy.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8 

    The article reports on the acquisition of Pfizer Inc. of the worldwide license to a novel human gene with Quark Biotech Inc. in the U.S. Under the deal, the former will develop the gene called RTP-801, and molecules that modify it that could have the potential to treat neovascular age-related...

  • Quark develops gene ID method.  // Crain's Cleveland Business;4/21/2003, Vol. 24 Issue 16, p8 

    Quark Biotech Inc. has developed a method for identifying genes that convey specific cellular functions. The Cleveland-based drug developer partnered with Louis Deiss of the University of Illinois at Chicago to develop the method they are calling the Achilles Heel Method. Deiss who is the...

  • How to Choose an In Vitro Kinase Assay. Shah, Anjani // Drug Discovery & Development;Mar2004, Vol. 7 Issue 3, p59 

    The decision whether to go with radioactive or fluorescent probes comes down to personal preference, number of samples to be analyzed, and substrate to be used. The basic components of the assay are simple namely a purified kinase, substrate, and ATP. But which substrate is used and how the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics